{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:28:47Z","timestamp":1790702927285,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients receiving interleukin (IL)\u2010inhibiting biologics for moderate\u2010to\u2010severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL\u2010inhibiting biologic treatment and \u22651 post\u2010induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients with non\u2010persistence were excluded. Expected daily dose (EDD) was calculated as the recommended maintenance dose divided by the treatment interval. Dose escalation was defined as \u22652 claims showing a \u226520% increase in the observed average daily dose (ADD) over the EDD (with sensitivities requiring \u22651 claim and \u226530%). Significant differences were tested using multivariable regressions. The study included 982 unique patients treated with brodalumab (BRO;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009104), guselkumab (GUS;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009207), ixekizumab (IXE;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009159), risankizumab (RIS;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009135), secukinumab (SEC;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009215) and ustekinumab (UST;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009196). Within 12\u2009months, dose escalation was observed for all IL\u2010inhibiting biologics other than GUS and RIS: 44.4% for UST, 37.2% for IXE, 3.4% for SEC and 1.4% for BRO. In multivariable\u2010adjusted analyses, odds of dose escalation were significantly lower for all products relative to UST. In sensitivities, escalation was observed for all products except RIS.\n                  <\/jats:p>","DOI":"10.1111\/exd.15067","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T03:19:14Z","timestamp":1715915954000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dose escalation of biologic treatment in patients with moderate\u2010to\u2010severe psoriasis in Japan"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Dermatology Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8632-1396","authenticated-orcid":false,"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-9508","authenticated-orcid":false,"given":"Kanako","family":"Ishii","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Sakuma","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital Frankfurt  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC  Milton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Nunag","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC  Milton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marric","family":"Buessing","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC  Milton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, IIB SANTPAU, Hospital de la Santa Creu i Sant Pau Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14145"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16214"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00559-z"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15023"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1247946"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.04.009"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13698"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419843118"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14782"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15146"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13001"},{"issue":"5","key":"e_1_2_11_13_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"5","author":"Sbidian E","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00647-0"},{"key":"e_1_2_11_15_1","unstructured":"WuJJ PatelM GaoW PhotowalaH GargV CrowleyJ.Real\u2010world dose escalation of biologics for patients with moderate to severe psoriasis. Poster presented at: Maui Derm connect; January 25\u201329 2021; Maui HI."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01064-1"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.5.583"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3636-3"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1937187"}],"updated-by":[{"DOI":"10.1111\/exd.15139","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.15067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:39:35Z","timestamp":1720687175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.15067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/exd.15067"],"URL":"https:\/\/doi.org\/10.1111\/exd.15067","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15067"}}